Generic Name and Formulations:
Azelaic acid 15%; aqueous gel; contains propylene glycol.
Indications for FINACEA:
Wash and dry skin. Massage thin layer gently into affected areas twice daily (AM & PM). May apply cosmetics after gel dries.
Monitor patients with dark complexions for hypopigmentation. Discontinue if sensitivity or severe irritation develops. Avoid eyes, mouth, other mucous membranes, occlusive dressings, topical alcoholic products, abrasives, peeling agents. Reevaluate if no improvement after 12 weeks of treatment. Foam: flammable. Pregnancy (Cat.B). Nursing mothers.
Burning, stinging, tingling, pruritus, scaling, dry skin, xerosis, erythema, irritation, edema, contact dermatitis, acne; worsening of asthma; foam: also application site pain.
Gel—50g tubes; Foam—50g cans
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking